Log in

NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

$13.28
-0.71 (-5.08 %)
(As of 12/16/2019 06:00 AM ET)
Today's Range
$13.19
Now: $13.28
$14.15
50-Day Range
$8.48
MA: $10.44
$14.69
52-Week Range
$5.41
Now: $13.28
$14.95
Volume90,318 shs
Average Volume239,637 shs
Market Capitalization$343.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$310,000.00
Book Value$3.79 per share

Profitability

Net Income$-34,500,000.00

Miscellaneous

Employees89
Market Cap$343.55 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.


Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.16. The biopharmaceutical company earned $3.50 million during the quarter. View Xenon Pharmaceuticals' Earnings History.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

What price target have analysts set for XENE?

2 Wall Street analysts have issued twelve-month price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 61.9% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

What is the consensus analysts' recommendation for Xenon Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News stories about XENE stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Xenon Pharmaceuticals.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 760,700 shares, an increase of 32.5% from the November 14th total of 574,100 shares. Based on an average daily trading volume, of 96,500 shares, the short-interest ratio is presently 7.9 days. Approximately 3.7% of the shares of the stock are short sold. View Xenon Pharmaceuticals' Current Options Chain.

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (2.34%), Granite Point Capital Management L.P. (1.15%), Granahan Investment Management Inc. MA (0.41%), Squarepoint Ops LLC (0.34%), California Public Employees Retirement System (0.24%) and Alps Advisors Inc. (0.20%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Granite Point Capital Management L.P., Squarepoint Ops LLC and Alps Advisors Inc.. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Supplemental Annuity Collective Trust of NJ, Granahan Investment Management Inc. MA, California Public Employees Retirement System and Tower Research Capital LLC TRC. View Insider Buying and Selling for Xenon Pharmaceuticals.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $13.28.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $343.55 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel